Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04637243

Outcomes From Treatment Liver and Bile Duct Diseases

It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. Our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity.

The main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Benign or Malignant Liver and Bile Duct Disease Bile Duct Diseases Biliary Tract Diseases Digestive System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Methodist Richardson Medical Center

Richardson, Texas, 75082, United States

About this study

The study will be a retrospective chart review of patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X. We plan to conduct an analysis of patients meeting the inclusion criteria form 2005 to present (up to the day before this study receives IRB approval). Charts will also be reviewed by the PI. Sub-I, Fellows, Office Staff, Clinical Research Coordinator who are delegated to do so by the PI. Data will be obtained from a national database. Data will be analyzed primarily by the study conductors.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients diagnosed and treated for liver and bile duct disease benign or malignant from 2005 to present (up to the day before this study receives IRB approval)
  • Age > 18 years

Exclusion criteria

  • Patients that are not diagnosed with or treated for liver and bile duct disease
  • Age < 18 years

Treatment and study plan

Treatment of Benign or Malignant Liver and Bile Duct Diseases

Other

Available treatment of Benign or Malignant Liver and Bile Duct Diseases

Primary outcomes

  1. Mortality from Treatment of Benign or Malignant Liver and Bile Duct Diseases

    Time frame: 2005 to 2019

    Mortality

  2. Morbidity from Treatment of Benign or Malignant Liver and Bile Duct Diseases

    Time frame: 2005 to 2019

    Morbidity

Sponsors and collaborators

Lead sponsor

Methodist Health System

Other

Registry information

Official study title

Evaluation of Outcomes From Treatment of Benign or Malignant Liver and Bile Duct Diseases

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Nov 19, 2020
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.